Changelog — 2026-02-13
2026-02-13
NVS
NOVARTIS AG
Enrollment 203→206 (1%) — PHASE2
NCT04589650
• Phase 2 • Enrollment 203→206 (+1%)
MEDIUM
2026-02-13
P
PHVS
Pharvaris N.V.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06669754
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-13
O
ONON
On Holding AG
Study arms updated — NA — investigator-sponsored (collaborator: ONON)
NCT06957743
• Na
MEDIUM
2026-02-13
MDT
Medtronic plc
Enrollment 50→100 (100%) — NA
NCT05144503
• Na • Enrollment 50→100 (+100%)
MEDIUM
2026-02-13
NVS
NOVARTIS AG
Enrollment 47→49 (4%) — PHASE2
NCT05849298
• Phase 2 • Enrollment 47→49 (+4%)
MEDIUM
2026-02-13
C
CHCO
CITY HOLDING CO
Enrollment 100→120 (20%) — PHASE4
NCT07333859
• Phase 4 • Enrollment 100→120 (+20%)
MEDIUM
2026-02-13
AZN
ASTRAZENECA PLC
Study arms updated — PHASE2 — investigator-sponsored (collaborator: AZN)
NCT02693535
• Phase 2
MEDIUM
2026-02-13
G
GMAB
GENMAB A/S
Enrollment 424→195 (-54%) — PHASE1
NCT04623541
• Phase 1 • Enrollment 424→195 (-54%)
MEDIUM
2026-02-13
NVS
NOVARTIS AG
Enrollment 165→163 (-1%) — PHASE4
NCT03975829
• Phase 4 • Enrollment 165→163 (-1%)
MEDIUM
2026-02-13
NVO
NOVO NORDISK A S
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT04596631
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-13
N
NVAX
NOVAVAX INC
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07079670
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-13
N
NVAX
NOVAVAX INC
Enrollment 120→676 (463%) — PHASE3
NCT07079670
• Phase 3 • Enrollment 120→676 (+463%)
MEDIUM
2026-02-13
MRK
Merck & Co., Inc.
Enrollment 30→34 (13%) — PHASE1
NCT06814119
• Phase 1 • Enrollment 30→34 (+13%)
MEDIUM
2026-02-13
A
AVDL
AVADEL PHARMACEUTICALS PLC
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT06525077
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-13
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT06162572
• Phase 1
MEDIUM
2026-02-13
REGN
REGENERON PHARMACEUTICALS, INC.
Enrollment 176→74 (-58%) — PHASE1
NCT06162572
• Phase 1 • Enrollment 176→74 (-58%)
MEDIUM